Clinical analysis of low-dose decitabine combined with CAG regimen in treatment of elderly patients with acute myeloid leukemia and myelodysplastic syndromes patients with intermediate- or high-risk
10.3760/cma.j.issn.1009-9921.2017.03.010
- VernacularTitle:小剂量地西他滨联合CAG方案治疗老年人急性髓系白血病及中高危骨髓增生异常综合征临床分析
- Author:
Ronghua HU
;
Wanling SUN
;
Hong ZHAO
;
Yixian GUO
;
Wuhan HUI
;
Suigui WAN
;
Li SU
- Keywords:
Leukemia;
myelocytic;
acute;
Myelodysplastic syndromes;
Decitabine;
Low-dose;
CAG regimen
- From:
Journal of Leukemia & Lymphoma
2017;26(3):166-169
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical value of low-dose decitabine (DAC) in elderly patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients with intermediate-or high-risk. Methods Low-dose DAC (10 mg/d, 7 days) combined with CAG regimen were given to 19 elderly patients with AML and intermediate- or high-risk MDS patients. The efficacy and adverse reactions were evaluated after a course of treatment, and the patients were followed up for survival. Results After a course of treatment, 8 patients achieved complete remission (CR), 7 patients achieved partial remission (PR). After 4 courses of treatment, 68.4 % (13/19) of patients achieved CR, the overall response rate reached 78.9% (15/19). Fewer side effects were seen associated with chemotherapy. After 42 months of follow-up, there were 12 survival cases, the median survival time was 13.5 months (3-42 months). Conclusion Low-dose DAC combined with CAG regimen have a better efficacy, higher safety, and lower economic burden for elderly AML patients and intermediate- or high-risk MDS patients, which is beneficial to greatly improve patients' compliance.
